Screening for Potential Serum-Based Proteomic Biomarkers for Human Type 2 Diabetes Mellitus Using Maldi-Tof Ms
Qiutao Meng,Siqi Ge,Wenhua Yan,Ruisheng Li,Jingtao Dou,Haibing Wang,Baoan Wang,Qingwei Ma,Yong Zhou,Manshu Song,Xinwei Yu,Hao Wang,Xinghua Yang,Fen Liu,Mohamed Ali Alzain,Yuxiang Yan,Ling Zhang,Lijuan Wu,Feifei Zhao,Yan He,Xiuhua Guo,Feng Chen,Weizhuo Xu,Monique Garcia,Desmond Menon,Youxin Wang,Yiming Mu,Wei Wang
DOI: https://doi.org/10.1002/prca.201600079
2016-01-01
Abstract:Background: Type 2 diabetes mellitus (T2DM) is a complex, pandemic disease contributing towards the global burden of health issues. To date, there are no simple clinical tests for the early detection of T2DM.Method: To identify potential peptide biomarkers for such applications, 406 sera of T2DM patients (n = 206) and healthy controls (n = 200) are analyzed by using MALDI-TOF MS with a cross-sectional case-control design.Result: Six peptides (peaks m/z 1452.9, 1692.8, 1946.0, 2115.1, 2211.0 and 4053.6) are identified as candidate biomarkers for T2DM. A diagnostic model constructed with six peptides is able to discriminate T2DM patients from healthy controls, with an accuracy of 82.20%, sensitivity of 82.50%, and specificity of 77.80% in the validation set. Peptide peaks m/z 1452.9 and 1692.8 are identified as fragments of the complement C3f, while peptide peaks m/z 1946.0, 2115.1, and 2211.0 are identified as the fragments of kininogen 1 isoform 1 precursor.Conclusion: This study reinforces proteomic analyses as a potential technique for defining significant clinical peptide biomarkers, providing a simple and convenient diagnostic model for T2DM in clinical examination.